Brokerages expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) to report $99.35 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Harmony Biosciences’ earnings. The highest sales estimate is $100.50 million and the lowest is $96.88 million. Harmony Biosciences posted sales of $73.82 million in the […]
Equities research analysts predict that Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) will post earnings of $0.40 per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Harmony Biosciences’ earnings, with the lowest EPS estimate coming in at $0.30 and the highest estimate coming in at $0.45. Harmony […]
Enochian Biosciences (NASDAQ:ENOB – Get Rating) and Harmony Biosciences (NASDAQ:HRMY – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings. Institutional & Insider Ownership 4.7% of Enochian Biosciences shares are […]
Analysts expect Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) to report earnings per share of $0.40 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Harmony Biosciences’ earnings, with estimates ranging from $0.30 to $0.45. Harmony Biosciences reported earnings per share of $0.54 during the same quarter […]
PTC Therapeutics (NASDAQ:PTCT – Get Rating) and Harmony Biosciences (NASDAQ:HRMY – Get Rating) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Volatility and Risk PTC Therapeutics has a beta of […]